Disease relevance of Restless Legs Syndrome

• The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review [1].
• BACKGROUND: Pramipexole, a new dopamine agonist, effectively treats early and advanced Parkinson disease and restless legs syndrome [2].
• Transverse myelitis associated with restless legs syndrome and periodic movements of sleep responsive to an oral dopaminergic agent but not to intrathecal baclofen [3].
• Two patients no longer needed levodopa; one of them had developed paraplegia and in the other the symptoms of restless legs syndrome had disappeared completely [4].
• The second group presented three syndromes (nocturnal paroxysmal dystonia, nocturnal myoclonus, restless legs syndrome), in which light non-rapid-eye-movement sleep induced a strong activation of abnormal movements, whereas rapid-eye-movement sleep suppressed them [5].

Psychiatry related information on Restless Legs Syndrome

• OBJECTIVE: To determine the occurrence of symptoms of attention-deficit/hyperactivity disorder (ADHD) in adults with restless legs syndrome (RLS), normal controls, and controls with insomnia [6].
• Sleepiness was measured by the Epworth Sleepiness Scale (ESS) while the presence of sleep disorders was evaluated by a score (SDS) drawn from indicators of insomnia, breathing disorders, periodic limb movements and restless legs syndrome, and hypersomnia [7].
• Nocturnal eating/drinking syndrome secondary to neuroleptic-induced restless legs syndrome (RLS) occurred under treatment with low-dose haloperidol in a 51-year-old female schizophrenic patient [8].
• We report on a family with comorbidity of Huntington's disease (HD) and idiopathic restless legs syndrome (RLS) [9].
• Since periodic limb movement disorder and/or restless legs syndrome can cause sleep disruption, we assessed whether these two specific sleep disorders are likely to occur in children with ADHD [10].

High impact information on Restless Legs Syndrome

• Folate deficiency and restless-legs syndrome in pregnancy [11].
• Levodopa in restless legs [12].
• The dopamine agonist bromocriptine may be a useful therapy in some patients with restless legs syndrome [13].
• Successful treatment of restless legs with clonazepam [14].
• Selective serotonin receptor uptake inhibitors can reduce restless legs symptoms [15].

Chemical compound and disease context of Restless Legs Syndrome

• L-Tryptophan in the treatment of restless legs syndrome [16].
• Propranolol in the treatment of restless legs syndrome induced by imipramine withdrawal [17].
• Encouraging initial response of restless legs syndrome to pramipexole [18].
• Treatment of idiopathic restless legs syndrome (RLS) with gabapentin [19].
• Restless legs syndrome induced by lithium [20].

Biological context of Restless Legs Syndrome

• An overview of levodopa in the management of restless legs syndrome in a dialysis population: pharmacokinetics, clinical trials, and complications of therapy [21].
• Brainstem and spinal pathways of untreated patients with idiopathic restless legs syndrome (RLS) were examined using magnetic resonance imaging (MRI), blink reflex, first and second exteroceptive suppression (ES1, ES2) of temporalis muscle, and H reflex [22].

Anatomical context of Restless Legs Syndrome

• Cerebrospinal fluid (CSF) and blood obtained from 22 untreated or scarcely treated patients with moderate to severe restless legs syndrome (RLS; mean age, 58.6 +/- 13 years) and 11 control subjects (mean age, 56.6 +/- 12.9 years) were investigated for biogenic amines between 6:00 and 8:00 PM [23].
• The aim of this study is evaluating iron, ferritin, and transferrin in both serum and CSF in patients of restless legs syndrome (RLS), based on the hypothesis that iron deficiency in the central nervous system (CNS) causes the symptoms as a result of the dysfunction of dopaminergic systems [24].

Gene context of Restless Legs Syndrome

• Evidence for a genetic association between monoamine oxidase A and restless legs syndrome [25].
• Mutational analysis of neurotensin in familial restless legs syndrome [26].
• Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome [27].
• Odds Ratios associated with Restless Legs were significantly increased in the fourth quintile of iron (OR 3.08 95 % CI 1.02-9.29) and transferrin saturation (OR 5.68 95 % CI 1.18-27.26) compared with the third (middle) quintile [28].
• To identify the prevalence and determinants of restless legs syndrome (RLS) in spinocerebellar ataxia (SCA) we studied 58 patients with a molecular diagnosis of SCA1, SCA2 and SCA3 [29].

Analytical, diagnostic and therapeutic context of Restless Legs Syndrome

• Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study [30].
• Normal IPT and IBZM SPECT in drug naive and levodopa-treated idiopathic restless legs syndrome [31].
• Pramipexole in Restless Legs syndrome. Evaluation by suggested immobilization test [32].
• Deep brain stimulation of the GPi treats restless legs syndrome associated with dystonia [33].
• We studied six restless legs syndrome (RLS) patients with [F18]fluorodeoxyglucose (FDG) positron emission tomography (PET) [34].

References